HEADLINES

More than a third of patients on Wegovy pill are new to GLP-1 drugs - report

Early data shows that 36% of patients using Novo Nordisk’s new Wegovy weight-loss pill had never taken a GLP-1 medication before, while others switched from injectable versions like Wegovy or Eli Lilly’s Zepbound. The findings come from a Truveta study of 8,762 U.S. patients following FDA approval in December 2025.

Robin Respaut/Reuters

February 12, 2026

FILE PHOTO: Wegovy pens are sorted at a packaging line at Novo Nordisk's facility in Hillerod, Denmark, March 8, 2024.

Tom Little/Reuters

Among early users of Novo Nordisk's NOVOb.COnew Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.

Of patients who started a new pill prescription, 21.1% had previously taken the injectable version of Wegovy and 15.8% switched from Eli Lilly's LLY.N Zepbound, another injectable GLP-1 medicine, according to Truveta data.

Truveta reviewed health records from 8,762 patients with evidence of a prescription for the new Wegovy pill, which was approved by the U.S. Food and Drug Administration on December 22.

-Robin Respaut/Reuters